Circadian rhythm of serum 25 (OH) vitamin D, calcium and phosphorus levels in the treatment and management of type-2 diabetic patients

Masood, Tariq; Kushwaha, Rajeev Singh; Singh, Ranjana; Sailwal, Shivani; Pandey, Himanshu; Varma, Amit; Singh, Randhir; Cornélissen, Germaine

doi:10.5582/ddt.2015.01002

Cited by 30 publications

(30 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The increase in sCa above normal range was not associated with any adverse signs, and beyond 24 hours postdose, sCa returned to the normal range. The small fluctuations in sCa over the 96‐hour observation period mimics the pattern found in humans where the circadian acrophase of sCa in healthy individuals occurs around noon . The sP levels in the monkeys remained within the normal range after administration of both dose levels of TransCon PTH (data not shown).…”

Section: Resultssupporting

confidence: 64%

Design and Preclinical Development of TransCon PTH, an Investigational Sustained-Release PTH Replacement Therapy for Hypoparathyroidism

Holten-Andersen

Pihl

Rasmussen

et al. 2019

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

Hypoparathyroidism (HP) is a condition of parathyroid hormone (PTH) deficiency leading to abnormal calcium and phosphate metabolism. The mainstay of therapy consists of vitamin D and calcium supplements, as well as adjunct Natpara (PTH(1‐84)). However, neither therapy optimally controls urinary calcium (uCa) or significantly reduces the incidence of hypercalcemia and hypocalcemia. TransCon PTH, a sustained‐release prodrug of PTH(1‐34) in development for the treatment of HP, was designed to overcome these limitations. To determine the pharmacokinetics and pharmacodynamics of TransCon PTH, single and repeat s.c. dose studies were performed in rats and monkeys. TransCon PTH demonstrated a half‐life of 28 and 34 hours in rats and monkeys, respectively. After repeated dosing, an infusion‐like profile of the released PTH, characterized by low peak‐to‐trough levels, was obtained in both species. In intact rats and monkeys, daily subcutaneous administration of TransCon PTH was associated with increases in serum calcium (sCa) levels and decreases in serum phosphate levels (sP). In monkeys, at a single dose of TransCon PTH that increased sCa levels within the normal range, a concurrent decrease in uCa excretion was observed. In 4‐week repeat‐dose studies in intact rats and monkeys, uCa excretion was comparable to controls across all dose levels despite increases in sCa levels. Further, in a rat model of HP, TransCon PTH normalized sCa and sP levels 24 hours per day. This was in contrast to only transient trends toward normalization of sCa and sP levels with an up to 6‐fold higher molar dose of PTH(1‐84). After repeated dosing to HP rats, uCa excretion transiently increased, corresponding to increases in sCa above normal range, but at the end of the treatment period, uCa excretion was generally comparable to sham controls. TransCon PTH was well tolerated and the observed pharmacokinetics and pharmacodynamics were in line with the expected action of physiological replacement of PTH. © 2019 American Society for Bone and Mineral Research.

show abstract

Section: Resultssupporting

confidence: 64%

Design and Preclinical Development of TransCon PTH, an Investigational Sustained-Release PTH Replacement Therapy for Hypoparathyroidism

Holten-Andersen

Pihl

Rasmussen

et al. 2019

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

show abstract

“…When daily central and peripheral rhythms are chronically disrupted or misaligned, the consequence of these circadian disruptions may be the development of metabolic disease [3]. Recent experimental studies [4,5,6] have suggested that the central circadian clock may also be regulated by another solar zeitgeber, vitamin D. Both 1,25-dihydroxycholecalciferol receptor (VDR) and 1α-hydroxylase (1α-OHase) were found to be widespread in human brain [4]. In adipose-derived stem cells, 1,25-dihydroxycholecalciferol was able to control the expression of circadian clock genes (i.e., BMAL1 and PER2) [5].…”

Section: Introductionmentioning

confidence: 99%

“…In adipose-derived stem cells, 1,25-dihydroxycholecalciferol was able to control the expression of circadian clock genes (i.e., BMAL1 and PER2) [5]. In addition, daily plasma 25-hydroxyvitamin D (25OHD) levels were reported to exhibit circadian oscillation [6]. Therefore, it is possible that vitamin D, otherwise known as the ‘sunshine vitamin’ [7], may influence circadian rhythms and related health outcomes.…”

Section: Introductionmentioning

confidence: 99%

Plasma Vitamin D Deficiency Is Associated With Poor Sleep Quality and Night-Time Eating at Mid-Pregnancy in Singapore

et al. 2017

View full text Add to dashboard Cite

Plasma 25-hydroxyvitamin D (25OHD) deficiency, poor sleep quality, and night-time eating, have been independently associated with adverse pregnancy outcomes, but their inter-relationships are yet to be evaluated. We aimed to investigate the associations between maternal plasma 25OHD status and sleep quality and circadian eating patterns during pregnancy. Data on pregnant women (n = 890) from a prospective cohort (Growing Up in Singapore Towards healthy Outcomes) were analyzed. Plasma 25OHD concentration was measured, while the Pittsburgh sleep quality index (PSQI) and 24-h dietary recall were administered to women at 26–28 weeks’ gestation. Plasma 25OHD status was defined as sufficient (>75 nmol/L), insufficient (50–75 nmol/L), or deficient (<50 nmol/L). Poor sleep quality was defined by a total global PSQI score >5. Predominantly day-time (pDT) and predominantly night-time (pNT) were defined according to consumption of greater proportion of calories (i.e., >50%) from 07:00–18:59 and from 19:00–06:59, respectively. After adjustment for confounders, women with plasma 25OHD deficiency had higher odds of poor sleep quality (odds ratio (OR) 3.49; 95% confidence interval (CI) 1.84–6.63) and pNT eating (OR: 1.85; 95% CI 1.00–3.41) than those who were 25OHD sufficient. Our findings show the association of maternal plasma 25OHD deficiency with poor sleep quality and pNT eating at mid-pregnancy.

show abstract

“…The HFnu was used to represent an index of parasympathetic activity, while the LFnu was used to represent an index of sympathetic activity in this study. AF episodes terminated during 06:00–22:00 represent diurnal events, and those during 22:00–06:00 represent nocturnal events . Decreased or increased LFnu and HFnu was defined as the data of the 0‐ to 5‐minute segment lower or higher than that of the 15‐ to 20‐minute segment.…”

Section: Methodsmentioning

confidence: 99%

“…AF episodes terminated during 06:00-22:00 represent diurnal events, and those during 22:00-06:00 represent nocturnal events. 17 Decreased or increased LFnu and HFnu was defined as the data of the 0-to 5-minute segment lower or higher than that of the 15-to 20-minute segment.…”

Section: Study Populationmentioning

confidence: 99%

Modulation of Autonomic Nervous Activity in the Termination of Paroxysmal Atrial Fibrillation

Huang

Lin

Hsieh

et al. 2017

Pacing Clinical Electrophis

View full text Add to dashboard Cite

show abstract

Circadian rhythm of serum 25 (OH) vitamin D, calcium and phosphorus levels in the treatment and management of type-2 diabetic patients

Cited by 30 publications

References 30 publications

Design and Preclinical Development of TransCon PTH, an Investigational Sustained-Release PTH Replacement Therapy for Hypoparathyroidism

Design and Preclinical Development of TransCon PTH, an Investigational Sustained-Release PTH Replacement Therapy for Hypoparathyroidism

Plasma Vitamin D Deficiency Is Associated With Poor Sleep Quality and Night-Time Eating at Mid-Pregnancy in Singapore

Modulation of Autonomic Nervous Activity in the Termination of Paroxysmal Atrial Fibrillation

Contact Info

Product

Resources

About